Company Overview of InteKrin Therapeutics Inc.
InteKrin Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for inflammatory and metabolic disorders. Its product includes INT-131, a peroxisome proliferator-activated receptor gamma modulator that targets inflammation and activates neuroprotective pathways. The company was founded in 2005 and is based in Redwood City, California. As of February 24, 2014, InteKrin Therapeutics Inc. operates as a subsidiary of Coherus Biosciences Inc.
201 Redwood Shores Parkway
Redwood City, CA 94065
Founded in 2005
Key Executives for InteKrin Therapeutics Inc.
Similar Private Companies By Industry
|Qwell Pharmaceuticals, Inc.||United States|
|AnosiaVax, Inc.||United States|
|Moderna Therapeutics, Inc.||United States|
|SymbioCellTech, LLC||United States|
|EnGen Bio, Inc.||United States|
Recent Private Companies Transactions
February 24, 2014
To contact InteKrin Therapeutics Inc., please visit www.intekrin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.